Abstract:In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile Dermatomyositis is a rare Pediatric Rheumatic Disease (PRD), associated with significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. Consequently, treatment regimens differ throughout Europe. To provide recommendations for diagnosis and treatment of JDM based on evidence-informed consensus. Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of 19 experienced paediatric rheumatologists and 2 experts in paediatric exercise physiology and physical therapy, mainly from Europe. Recommendations derived from a validated systematic literature review were evaluated by an online survey and subsequently discussed at two consensus meetings using nominal group technique. Recommendations were accepted if >80% agreement was reached. In total, 7 overarching principles, 33 recommendations on diagnosis and 19 recommendations on therapy were accepted with >80% agreement among experts. Topics covered include assessment of skin, muscle and major organ involvement and suggested treatment pathways. The SHARE initiative aims to identify best practices for treatment of patients suffering from PRD. Within this remit, recommendations for the diagnosis and treatment of JDM have been formulated by an evidence-informed consensus process to produce a standard of care for patients with JDM throughout Europe. B. Bader-Meunier (Department for Immunology, Hematology and Pediatric Rheumatology, Necker Hospital, Paris, France), E. Baildam (Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, UK), T. Constantin (Semmelweis Hospital, Budapest, Hungary), B. Feldman (Department of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada.), P. Lahdenne (Department of Pediatric Rheumatology, Children's Hospital, Helsinki University Central Hospital, Helsinki), B. Magnusson (Astrid Lindgren Children's Hospital, Department for Pediatric Rheumatology, Karolinska University HospitalStockholm, Sweden), K. Nistala (Centre for Rheumatology, University College London, UK), C. Pilkington (Centre for Rheumatology, University College London, UK), A. Ravelli (Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy), R. Russo (Service of Immunology and Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina), M. van Brussel (Child Development and Exercise Center, Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands), JJ. van der Net (Child Development and Exercise Center, Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands), L. Wedderburn (Centre for Rheumatology, University College London, UK), N. Wulffraat (Department of Pediatric Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands), B. Bader-Meunier (Department for Immunology, Hematology and Pediatric Rheumatology, Necker Hospital, Paris, France), E. Baildam (Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, UK), T. Constantin (Semmelweis Hospital, Budapest, Hungary), B. Feldman (Department of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada), P. Lahdenne (Department of Pediatric Rheumatology, Children's Hospital, Helsinki University Central Hospital, Helsinki), B. Magnusson (Astrid Lindgren Children's Hospital, Department for Pediatric Rheumatology, Karolinska University HospitalStockholm, Sweden), K. Nistala (Centre for Rheumatology, University College London, UK), C. Pilkington (Centre for Rheumatology, University College London, UK), A. Ravelli (Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy), R. Russo (Service of Immunology and Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina). None declared

SP0036 Share recommendations on juvenile dermatomyositis

Consensus-based recommendations for the management of juvenile dermatomyositis

The Efficacy of Baricitinib in Real-World Patients with Refractory or Severe Juvenile Dermatomyositis:A Monocentric Retrospective Study

Janus Kinase Inhibitor, Tofacitinib, in Refractory Juvenile Dermatomyositis: a Retrospective Multi-Central Study in China

P094 Comprehensive comparison of juvenile-onset systemic lupus erythematosus guidelines for diagnosis and management to those used in adult-onset disease

European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative

Mapping the current psychology provision for children and young people with juvenile dermatomyositis

European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative

Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

OA34 Unravelling the role of B cells and interferon dysregulation in juvenile dermatomyositis

Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice

Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies

P089 Comprehensive comparison of current guidelines in the management of Systemic Lupus Erythematosus in children, with a focus on Lupus Nephritis

25 Years of Biologics For The Treatment of Pediatric Rheumatic Diseases – Advances in Prognosis and Ongoing Challenges

Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature

Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials

Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome

Is There a Link between the Molecular Basis of Juvenile Idiopathic Arthritis and Autoimmune Diseases? Systematic Review

Favorable outcomes with reduced steroid use in juvenile dermatomyositis